The high prices charged by companies for cancer drugs has led to lots of speculation, but very little explanation. The most interesting attempt to explain these high prices has been […]
Tag: NICE
James Raftery: The government response to the value based pricing consultation
The publication of the Government response to the value based pricing consultation provides some further insight into current thinking. 188 responses are summarised to the 20 questions posed in the consultation, along […]
James Raftery: What does “value based pricing” mean for NICE?
The “value based pricing” consultation paper” makes the following relevant references to the future of the National Institute for Health and Clinical Excellence (NICE). […]
James Raftery: Value based pricing – the consultation paper
The publication of the Department of Health’s consultation paper on value based pricing and the ongoing consultation on the Cancer Drugs Fund plus each consultation’s accompanying impact assessment mean that […]
James Raftery on NICE’s cost per QALY threshold: does the public have a view?
One approach to setting NICE’s cost per QALY threshold might be to survey the public. In 2003 NICE and the Department of Health did just that, with a study “assessing […]
James Raftery on a greater role for industry in NICE’s cost per QALY?
In December 2008 the Department of Health in England published the Pharmaceutical Price Regulation Scheme. It describes how the scheme will operate for at least five years from 2009. The previous scheme was […]
Vidhya Alakeson on US health reform
As with his presidential campaign, Barack Obama’s approach to health reform will leave little to chance. His strategy for enacting the first major coverage expansion in more than 40 years […]
Joe Collier: A stab at future UK Drug Pricing Policy
We are now into the fifth month of the negotiations to reform the secretive and perverse (and essentially discredited) UK Pharmaceutical Price Regulation Scheme (PPRS), and we can safely assume […]